Down-regulation of allergic responses in conditions of experimental diabetes: A role for glucocorticoids?

NeuroImmunoModulation

Volumn 16, Issue 1, 2009, Pages 13-18

  E Silva, Patrícia M R ^a   Carvalho, Vinicius F ^a   Cordeiro, Renato S B ^a   Martins, Marco A ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Atopy; Diabetes; Glucocorticoids; Hypothalamic pituitary adrenocortical axis; Mast cells

Indexed keywords

GLUCOCORTICOID;

ALLERGIC ASTHMA; ALLERGIC CONJUNCTIVITIS; ALLERGIC REACTION; ATOPIC DERMATITIS; ATOPY; DOWN REGULATION; EXPERIMENTAL DIABETES MELLITUS; HUMAN; HYPERCORTISOLISM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSULIN DEPENDENT DIABETES MELLITUS; MAST CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 57449088686     PISSN: 10217401     EISSN: None     Source Type: Journal    
DOI: 10.1159/000179662     Document Type: Review

References (75)

1. Tisch R, McDevitt H: Insulin-dependent diabetes mellitus. Cell 1996;85:291-297.
2. Bell GI, Polonsky KS: Diabetes mellitus and genetically programmed defects in beta-cell function. Nature 2001;414:788-791.
3. Zimmet P, Alberti KG, Shaw J: Global and societal implications of the diabetes epidemic. Nature 2001;414:782-787.
4. Atkinson MA, Maclaren NK: The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med 1994;331:1428-1436.
5. Hoet JJ, Tripathy BB: Report of the International Workshop on types of Diabetes Peculiar to the Tropics. Diabetes Care 1996;19:1014.
6. Klip A, Marette A, Dimitrakoudis D, Ramlal T, Giacca A, Shi ZQ, Vranic M: Effect of diabetes on glucoregulation. From glucose transporters to glucose metabolism in vivo. Diabetes Care 1992;15:1747-1766.
7. Taskinen MR, Lahdenpera S, Syvanne M: New insights into lipid metabolism in non-insulin-dependent diabetes mellitus. Ann Med 1996;28:335-340.
8. Vlassara H, Brownlee M, Cerami A: Accumulation of diabetic rat peripheral nerve myelin by macrophages increases with the presence of advanced glycosylation end-products. J Exp Med 1984;160:197-207.
9. Yabe-Nishimura C: Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol Rev 1998;50:21-33.
10. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-820.
11. Larkin JG, Frier BM, Ireland JT: Diabetes mellitus and infection. Postgrad Med J 1985;61:233-237.
12. Garcia-Leme J, Fortes ZB, Sanomiya P, Farsky SP: Insulin, glucocorticoids and the control of inflammatory responses. Agents Actions Suppl 1992;36:99-118.
13. De Luis DA, Aller R: Diabetes mellitus and Helicobacter pylori infection (in Spanish). Med Clin (Barc) 2001;117:627-631.
14. Rayfield EJ, Ault MJ, Keusch GT, Brothers MJ, Nechemias C, Smith H: Infection and diabetes: the case for glucose control. Am J Med 1982;72:439-450.
15. Gupta S, Koirala J, Khardori R, Khardori N: Infections in diabetes mellitus and hyperglycemia. Infect Dis Clin North Am 2007;21:617-638, vii.
16. Kontras SB, Bodenbender JG: Studies of the inflammatory cycle in juvenile diabetes. Am J Dis Child 1968;116:130-134.
17. Rerup CC: Drugs producing diabetes through damage of the insulin-secreting cells. Pharmacol Rev 1970;22:485-518.
18. Gaulton GN, Schwartz JL, Eardley DD: Assessment of the diabetogenic drugs alloxan and streptozotocin as models for the study of immune defects in diabetic mice. Diabetologia 1985;28:769-775.
19. Quan N, Ho E, La W, Tsai YH, Bray T: Administration of NF-κB decoy inhibits pancreatic activation of NF-κB and prevents diabetogenesis by alloxan in mice. FASEB J 2001;15:1616-1618.
20. Im Walde SS, Dohle C, Schott-Ohly P, Gleichmann H: Molecular target structures in alloxan-induced diabetes in mice. Life Sci 2002;71:1681-1694.
21. Garcia-Leme J, Bohm GH, Migliorini RH, de Souza MZ: Possible participation of insulin in the control of vascular permeability. Eur J Pharmacol 1974;29:298-306.
22. Fortes ZB, Garcia Leme J, Scivoletto R: Vascular reactivity in diabetes mellitus: possible role of insulin on the endothelial cell. Br J Pharmacol 1984;83:635-643.
23. Akamine EH, Hohman TC, Nigro D, Carvalho MH, de Cássia Tostes R, Fortes ZB: Minalrestat, an aldose reductase inhibitor, corrects the impaired microvascular reactivity in diabetes. J Pharmacol Exp Ther 2003;304:1236-1242.
24. Wertman KF, Henney MR: The effects of alloxan diabetes on phagocytosis and susceptibility to infection. J Immunol 1962;89:314-317.
25. Mowat A, Baum J: Chemotaxis of polymorphonuclear leukocytes from patients with diabetes mellitus. N Engl J Med 1971;284:621-627.
26. Fortes ZB, Farsky SP, Oliveira MA, Garcia-Leme J: Direct vital microscopic study of defective leukocyte-endothelial interaction in diabetes mellitus. Diabetes 1991;40:1267-1273.
27. Bottini N, Fontana L: Asthma and diabetes. Lancet 1999;354:515-516.
28. Olesen AB, Juul S, Birkebaek N, Thestrup-Pedersen K: Association between atopic dermatitis and insulin-dependent diabetes mellitus: a case-control study. Lancet 2001;357:1749-1752.
29. Feizy V, Ghobadi A: Atopic dermatitis and systemic autoimmune diseases: a descriptive cross sectional study. Dermatol Online J 2006;12:3.
30. Bostancy I, Dallar Y, Unsal Sac R, Karakoc E, Doganay B: Latex allergy risk assessment in children and adolescents with type I diabetes mellitus. Pediatr Allergy Immunol 2007;18:687-691.
31. Tzeng ST, Hsu SG, Fu LS, Chi CS: Prevalence of atopy in children with type 1 diabetes mellitus in central Taiwan. J Microbiol Immunol Infect 2007;40:74-78.
32. Caffarelli C, Cavagni G, Pierdomenico R, Chiari G, Spattini A, Vanelli M: Coexistence of IgE-mediated allergy and type 1 diabetes in childhood. Int Arch Allergy Immunol 2004;134:288-294.
33. Rabin RL, Levinson AI: The nexus between atopic disease and autoimmunity: a review of the epidemiological and mechanistic literature. Clin Exp Immunol 2008;153:19-30.
34. Shi HN, Walker WA: T helper cell subclasses and clinical disease states. Curr Opin Gastroenterol 2002;18:711-716.
35. Singh VK, Mehrotra S, Agarwal SS: The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy. Immunol Res 1999;20:147-161.
36. Rapoport MJ, Lazarus AH, Jaramillo A, Speck E, Delovitch TL: Thymic T cell anergy in autoimmune nonobese diabetic mice is mediated by deficient T cell receptor regulation of the pathway of p21ras activation. J Exp Med 1993;177:1221-1226.
37. Mirel DB, Valdes AM, Lazzeroni LC, Reynolds RL, Erlich HA, Noble JA: Association of IL4R haplotypes with type 1 diabetes. Diabetes 2002;51:3336-3341.
38. Rapoport MJ, Jaramillo A, Zipris D, Lazarus AH, Serreze DV, Leiter EH, Cyopick P, Danska JS, Delovitch TL: Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med 1993;178:87-99.
39. Cooke A: Th17 cells in inflammatory conditions. Rev Diabet Stud 2006;3:72-75.
40. Oboki K, Ohno T, Saito H, Nakae S: Th17 and allergy. Allergol Int 2008;57:121-134.
41. Jain R, Tartar DM, Gregg RK, Divekar RD, Bell JJ, Lee HH, Yu P, Ellis JS, Hoeman CM, Franklin CL, Zaghouani H: Innocuous IFNγ induced by adjuvant-free antigen restores normoglycemia in NOD mice through inhibition of IL-17 production. J Exp Med 2008;205:207-218.
42. Diaz BL, Serra MF, Alves AC, Pires AL, Corrêa FM, Cordeiro RS, Martins MA, Silva PM: Alloxan diabetes reduces pleural mast cell numbers and the subsequent eosinophil influx induced by allergen in sensitized rats. Int Arch Allergy Immunol 1996;111:36-43.
43. Diaz BL, Serra MF, Barreto EO, Cordeiro RS, Martins MA, Silva PM: Antigen-induced pleural eosinophilia is suppressed in diabetic rats: role of corticosteroid hormones. Mem Inst Oswaldo Cruz 1997;92(suppl 2):219-222.
44. Vianna EO, Garcia-Leme J: Allergen-induced airway inflammation in rats. Role of insulin. Am J Respir Crit Care Med 1995;151(3 pt 1):809-814.
45. de Oliveira Barreto E, de Frias Carvalho V, Diaz BL, Balduino A, Cordeiro RS, Martins MA, Rodrigues e Silva PM: Adoptive transfer of mast cells abolishes the inflammatory refractoriness to allergen in diabetic rats. Int Arch Allergy Immunol 2003;131:212-220.
46. de F Carvalho V, Campos LV, Farias-Filho FA, Florim LT, Barreto EO, Pirmez C, Savino W, Martins MA, E Silva PM: Suppression of the allergic inflammatory response in the skin of alloxan-diabetic rats: relationship with reduced local mast cell numbers. Int Arch Allergy Immunol 2008;147:246-254.
47. Metcalfe DD, Baram D, Mekori YA: Mast cells. Physiol Rev 1997;77:1033-1079.
48. Galli SJ: New insights into 'the riddle of the mast cells': microenvironmental regulation of mast cell development and phenotypic heterogeneity. Lab Invest 1990;62:5-33.
49. Galli SJ, Nakae S, Tsai M: Mast cells in the development of adaptive immune responses. Nat Immunol 2005;6:135-142.
50. Kawakami T, Galli SJ: Regulation of mast-cell and basophil function and survival by IgE. Nat Rev Immunol 2002;2:773-786.
51. Hogan AD, Schwartz LB: Markers of mast cell degranulation. Methods 1997;13:43-52.
52. Tsai M, Grimbaldeston MA, Yu M, Tam SY, Galli SJ: Using mast cell knock-in mice to analyze the roles of mast cells in allergic responses in vivo. Chem Immunol Allergy 2005;87:179-197.
53. Barreto EO, Carvalho VF, Lagente V, Lugnier C, Cordeiro RS, Martins MA, E Silva PM: Increased levels of cyclic adenosine monophosphate contribute to the hyporesponsiveness of mast cells in alloxan diabetes. Int Immunopharmacol 2004;4:755-762.
54. Barreto EO, Carvalho VF, Oliveira MS, Bertho AL, Barja-Fidalgo TC, Cordeiro RS, Martins MA, Silva PM: High levels of filamentous actin and apoptosis correlate with mast cell refractoriness under alloxan-evoked diabetes. Life Sci 2006;79:1194-1202.
55. Ganley OH: Studies on the prevention of sensitization by Bordetella pertussis in alloxan diabetic mice. Can J Biochem Physiol 1962;40:1179-1183.
56. Dhar HL, Sanyal RK, West GB: The relationship of the blood sugar level to the severity of anaphylactic shock. Br J Pharmacol Chemother 1967;31:351-355.
57. Carvalho VF, Barreto EO, Diaz BL, Serra MF, Azevedo V, Cordeiro RS, Martins MA, Silva PM: Systemic anaphylaxis is prevented in alloxan-diabetic rats by a mechanism dependent on glucocorticoids. Eur J Pharmacol 2003;472:221-227.
58. Ptak W, Rewicka M, Stryzewska J, Kollat M: Alleviation of IgE-mediated immune reactions in hypoinsulinaemic and hyperglycaemic mice. Clin Exp Immunol 1983;52:54-60.
59. Adcock IM, Ito K, Barnes PJ: Glucocorticoids: effects on gene transcription. Proc Am Thorac Soc 2004;1:247-254.
60. Barnes PJ, Hansel TT: Prospects for new drugs for chronic obstructive pulmonary disease. Lancet 2004;364:985-996.
61. Schleimer RP: An overview of glucocorticoid anti-inflammatory actions. Eur J Clin Pharmacol 1993;45(suppl 1):S3-S7.
62. Da Silva CA, Frossard N: Regulation of stem cell factor expression in inflammation and asthma. Mem Inst Oswaldo Cruz 2005;100(suppl 1):145-151.
63. Finotto S, Mekori YA, Metcalfe DD: Glucocorticoids decrease tissue mast cell number by reducing the production of the c-kit ligand, stem cell factor, by resident cells: in vitro and in vivo evidence in murine systems. J Clin Invest 1997;99:1721-1728.
64. Puxeddu I, Piliponsky AM, Bachelet I, Levi-Schaffer F: Mast cells in allergy and beyond. Int J Biochem Cell Biol 2003;35:1601-1607.
65. Pipkorn U, Hammarlund A, Enerback L: Prolonged treatment with topical glucocorticoids results in an inhibition of the allergen-induced weal-and-flare response and a reduction in skin mast cell numbers and histamine content. Clin Exp Allergy 1989;19:19-25.
66. Goldsmith P, McGarity B, Walls AF, Church MK, Millward-Sadler GH, Robertson DA: Corticosteroid treatment reduces mast cell numbers in inflammatory bowel disease. Dig Dis Sci 1990;35:1409-1413.
67. Barnes PJ: Molecular mechanisms of glucocorticoid action in asthma. Pulm Pharmacol Ther 1997;10:3-19.
68. Cameron OG, Kronfol Z, Greden JF, Carroll BJ: Hypothalamic-pituitary- adrenocortical activity in patients with diabetes mellitus. Arch Gen Psychiatry 1984;41:1090-1095.
69. Roy M, Collier B, Roy A: Hypothalamic-pituitary-adrenal axis dysregulation among diabetic outpatients. Psychiatry Res 1990;31:31-37.
70. Roy MS, Roy A, Brown S: Increased urinary-free cortisol outputs in diabetic patients. J Diabetes Complications 1998;12:24-27.
71. Bruehl H, Rueger M, Dziobek I, Sweat V, Tirsi A, Javier E, Arentoft A, Wolf OT, Convit A: Hypothalamic-pituitary-adrenal axis dysregulation and memory impairments in type 2 diabetes. J Clin Endocrinol Metab 2007;92:2439-2445.
72. Chan O, Inouye K, Riddell MC, Vranic M, Matthews SG: Diabetes and the hypothalamo-pituitary-adrenal (HPA) axis. Minerva Endocrinol 2003;28:87-102.
73. Noguchi S, Ohno Y, Aoki N: Adrenocortical insufficiency in Otsuka Long-Evans Tokushima Fatty rats, a type 2 diabetes mellitus model. Metabolism 2007;56:1326-1333.
74. Diaz B, Barreto E, Cordeiro R, Perretti M, Martins M, Silva P: Enhanced serum glucocorticoid levels mediate the reduction of serosal mast cell numbers in diabetic rats. Life Sci 2001;68:2925-2932.
75. Cuman RK, Bersani-Amado CA, Fortes ZB: Influence of type 2 diabetes on the inflammatory response in rats. Inflamm Res 2001;50:460-465.